

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Ascletis Pharma Inc.
歌禮製藥有限公司

(incorporated in the Cayman Islands with limited liability)

(Stock code: 1672)

**POLL RESULTS OF ANNUAL GENERAL MEETING
HELD ON JUNE 6, 2019**

References are made to the notice (the “**AGM Notice**”) of the annual general meeting (the “**AGM**”) and the circular (the “**Circular**”) of Ascletis Pharma Inc. (the “**Company**”) both dated May 7, 2019. Unless otherwise indicated, capitalised terms used herein have the same meanings as those defined in the Circular.

POLL RESULTS OF AGM

At the AGM held on June 6, 2019, a poll was demanded by the chairman of the AGM for voting on all the resolutions (the “**Proposed Resolutions**”) proposed at the AGM as set out in the AGM Notice.

As at the date of the AGM, the total number of issued Shares was 1,120,685,000 Shares, all of which entitled the holders to attend and vote for or against the Proposed Resolutions at the AGM. There were no restrictions on any Shareholders to cast votes on any of the Proposed Resolutions at the AGM. There were no Shares entitling the Shareholders to attend and abstain from voting in favour of any of the Proposed Resolutions at the AGM as set out in Rule 13.40 of the Listing Rules. No Shareholder was required under the Listing Rules to abstain from voting on the Proposed Resolutions. None of the Shareholders have indicated in the Circular that they intended to vote against or to abstain from voting on any Proposed Resolutions at the AGM.

The Company's branch share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited, was appointed as the scrutineer at the AGM for the purpose of vote-taking at the AGM.

The poll results in respect of all the Proposed Resolutions were as follows:

Ordinary Resolutions		No. of Votes (%)	
		For	Against
1.	To receive and consider the audited consolidated financial statements of the Company and its subsidiaries and the reports of the directors and auditor for the year ended December 31, 2018.	821,467,915 (100.00000%)	0 (0.00000%)
2.	(i) To re-elect Dr. Jinzi Jason WU as an executive Director	815,919,755 (99.324604%)	5,548,160 (0.675396%)
	(ii) To re-elect Mrs. Judy Hejingdao WU as an executive Director	821,467,915 (100.00000%)	0 (0.00000%)
	(iii) To authorize the board of Directors to fix the remuneration of the Directors	821,467,915 (100.00000%)	0 (0.00000%)
3.	To re-appoint Ernst & Young as auditor and to authorize the board of Directors to fix its remuneration	821,467,915 (100.00000%)	0 (0.00000%)
4.	To grant a general mandate to the Directors to issue new shares of the Company not exceeding 20% of the total number of issued shares of the Company	718,826,893 (87.505170%)	102,641,022 (12.494830%)
5.	To grant a general mandate to the Directors to repurchase shares of the Company not exceeding 10% of the total number of issued shares of the Company	821,467,915 (100.00000%)	0 (0.00000%)
6.	To extend the general mandate to issue new shares by adding the number of shares repurchased	773,614,893 (94.174694%)	47,853,022 (5.825306%)

As more than 50% of the votes present at the AGM in person or by proxy were cast in favour of each of the above ordinary resolutions numbered 1 to 6, all the Proposed Resolutions were duly passed as ordinary resolutions of the Company.

By order of the Board
Ascletis Pharma Inc.
歌禮製藥有限公司
Jinzi Jason WU
Chairman

Hangzhou, the People's Republic of China
June 6, 2019

As at the date of this announcement, the Board of Directors of the Company comprises Dr. Jinzi Jason WU and Mrs. Judy Hejingdao WU, as executive Directors; and Dr. Ru Rong JI, Dr. Yizhen WEI, Mr. Jiong GU and Ms. Lin HUA, as independent non-executive Directors.